Recent developments and applications of quantitative proteomics strategies for high-throughput biomolecular analyses in cancer research,RSC Chemical Biology

当前位置： X-MOL 学术 › RSC Chem. Biol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recent developments and applications of quantitative proteomics strategies for high-throughput biomolecular analyses in cancer research
RSC Chemical Biology ( IF 4.2 ) Pub Date : 2021-5-19 , DOI: 10.1039/d1cb00039j
Hannah N Miles ₁ , Daniel G Delafield ₂ , Lingjun Li _{1,

2}

Affiliation

Innovations in medical technology and dedicated focus from the scientific community have inspired numerous treatment strategies for benign and invasive cancers. While these improvements often lend themselves to more positive prognoses and greater patient longevity, means for early detection and severity stratification have failed to keep pace. Detection and validation of cancer-specific biomarkers hinges on the ability to identify subtype-specific phenotypic and proteomic alterations and the systematic screening of diverse patient groups. For this reason, clinical and scientific research settings rely on high throughput and high sensitivity mass spectrometry methods to discover and quantify unique molecular perturbations in cancer patients. Discussed within is an overview of quantitative proteomics strategies and a summary of recent applications that enable revealing potential biomarkers and treatment targets in prostate, ovarian, breast, and pancreatic cancer in a high throughput manner.

中文翻译：

癌症研究中高通量生物分子分析定量蛋白质组学策略的最新发展和应用

医疗技术的创新和科学界的专注激发了许多良性和侵袭性癌症的治疗策略。虽然这些改进往往有助于获得更积极的预后和更长的患者寿命，但早期检测和严重程度分层的手段却未能跟上步伐。癌症特异性生物标志物的检测和验证取决于识别亚型特异性表型和蛋白质组改变的能力以及对不同患者群体的系统筛查。因此，临床和科学研究机构依靠高通量和高灵敏度的质谱方法来发现和量化癌症患者中独特的分子扰动。其中讨论的是定量蛋白质组学策略的概述以及最近应用的总结，这些应用能够以高通量方式揭示前列腺癌、卵巢癌、乳腺癌和胰腺癌的潜在生物标志物和治疗靶点。

更新日期：2021-05-28

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文